New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions
Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions CLINICAL TRANSPLANTATION Epailly, E., Albanell, J., Andreassen, A., Bara, C., Campistol, J. M., Delgado, J. F., Eisen, H., Fiane, A. E., Mohacsi, P., Schubert, S., Sebbag, L., Turazza, F. M., Valantine, H., Zuckermann, A., Potena, L. 2011; 25 (5): E475-E486Abstract
Although malignancy is a major threat to long-term survival of heart transplant (HT) recipients, clear strategies to manage immunosuppression in these patients are lacking. Several lines of evidences support the hypothesis of an anticancer effect of proliferation signal inhibitors (PSIs: mammalian target of rapamycin [mTOR] inhibitors) in HT recipients. This property may arise from PSI's ability to replace immunosuppressive therapies that promote cancer progression, such as calcineurin inhibitors or azathioprine, and/or through their direct biological actions in preventing tumor development and progression. Given the lack of randomized studies specifically exploring these issues in the transplant setting, a collaborative group reviewed current literature and personal clinical experience to reach a consensus aimed to provide practical guidance for the clinical conduct in HT recipients with malignancy, or at high risk of malignancy, with a special focus on advice relevant to potential role of PSIs.
View details for DOI 10.1111/j.1399-0012.2011.01476.x
View details for Web of Science ID 000296262300002
View details for PubMedID 21592231